Drug Profile
Daptomycin intravenous - Viatris/Avecho Biotechnology
Alternative Names: TPM®/Daptomycin Lyophilized Powder for IV Injection; TPM® DaptomycinLatest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Phosphagenics
- Developer Avecho Biotechnology; Viatris Inc
- Class Antibacterials; Cyclic peptides; Lipopeptides; Peptide antibiotics; Small molecules
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bacteraemia; Skin and soft tissue infections
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for preclinical development in Skin-and-soft-tissue-infections in USA (IV, Injection)
- 24 Mar 2020 Preclinical development in Skin-and-soft-tissue-infections is ongoing in USA (IV, Injection) (Phosphagenics pipeline, March 2020)
- 28 Dec 2018 No development reported for Preclinical for Bacteraemia in USA (IV, Injection)